학술논문
Beneficial effect of temporary methotrexate interruption on B and T cell responses upon SARS-CoV-2 vaccination in patients with rheumatoid arthritis or psoriatic arthritis
Document Type
article
Author
Pedro Martínez-Fleta; Esther F. Vicente-Rabaneda; Ana Triguero-Martínez; Emilia Roy-Vallejo; Miren Uriarte-Ecenarro; Francisco Gutiérrez-Rodríguez; Patricia Quiroga-Colina; Ana Romero-Robles; Nuria Montes; Noelia García-Castañeda; Gina P. Mejía-Abril; Jesús A. García-Vadillo; Irene Llorente-Cubas; José R. Villagrasa; José M. Serra López-Matencio; Julio Ancochea; Ana Urzainqui; Laura Esparcia-Pinedo; Arantzazu Alfranca; Hortensia de la Fuente; Rosario García-Vicuña; Francisco Sánchez-Madrid; Isidoro González-Álvaro; Santos Castañeda
Source
npj Vaccines, Vol 9, Iss 1, Pp 1-9 (2024)
Subject
Language
English
ISSN
2059-0105
Abstract
Abstract B and T cell responses were evaluated in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) after 1 or 2 weeks of methotrexate (MTX) withdrawal following each COVID-19 vaccine dose and compared with those who maintained MTX. Adult RA and PsA patients treated with MTX were recruited and randomly assigned to 3 groups: MTX-maintenance (n = 72), MTX-withdrawal for 1 week (n = 71) or MTX-withdrawal for 2 weeks (n = 73). Specific antibodies to several SARS-CoV-2 antigens and interferon (IFN)-γ and interleukin (IL)-21 responses were assessed. MTX withdrawal in patients without previous COVID-19 was associated with higher levels of anti-RBD IgG and neutralising antibodies, especially in the 2-week withdrawal group and with higher IFN-γ secretion upon stimulation with pools of SARS-CoV-2 S peptides. No increment of RA/PsA relapses was detected across groups. Our data indicate that two-week MTX interruption following COVID-19 vaccination in patients with RA or PsA improves humoral and cellular immune responses.